Nasal zavegepant provides fast migraine pain relief comparable to oral CGRP receptor antagonists but doesn't show clear superiority in efficacy or long-term symptom relief.
11,179 patients across 15 RCTsThis large network meta-analysis found zavegepant nasal spray was effective versus placebo (RR 1.54 for 2-hour pain freedom) but comparable — not superior — to oral CGRP antagonists.
What the researchers found
Across 15 RCTs with 11,179 patients, zavegepant 10 mg nasal inhalation significantly outperformed placebo for pain freedom at 2 hours (RR = 1.54, 95% CI: 1.28-1.82) and most bothersome symptom freedom at 2 hours. However, zavegepant did not demonstrate significant superiority over oral CGRP receptor antagonists in either efficacy or long-term symptom relief. On safety, zavegepant 10 mg had more adverse events than placebo but was not inferior to oral gepants.
Why it matters
For migraine patients who struggle with oral medications (due to nausea, vomiting, or need for faster onset), a nasal spray alternative is clinically important. This meta-analysis clarifies that while zavegepant nasal spray is effective and safe, it doesn't outperform oral gepants — helping clinicians and patients make informed treatment decisions based on convenience and individual needs rather than expecting superior efficacy.
How the study worked
Systematic review and network meta-analysis searching PubMed, EMBASE, Cochrane, Scopus, and Web of Science through December 2024. Included only randomized controlled trials of CGRP receptor antagonists for acute migraine in adults, excluding non-randomized, non-English, or non-extractable data trials. Statistical analysis performed using STATA 18.0 and R Studio with network meta-analysis methodology enabling indirect comparisons between treatments.
What this study cannot tell us
Network meta-analysis relies on indirect comparisons between drugs that weren't tested head-to-head, which introduces uncertainty. The included trials may have different designs, patient populations, and outcome definitions. Only English-language publications were included, potentially missing relevant data. The analysis focused on acute (single-attack) treatment and may not reflect real-world patterns of repeated use.
How to read the evidence
Network meta-analysis of randomized controlled trials represents high-quality evidence. The large total sample size (11,179 patients) and systematic methodology strengthen confidence. However, indirect comparisons between drugs carry more uncertainty than direct head-to-head trials.
When this study was published
Published in 2025 with searches through December 2024, this is one of the most current comparisons of CGRP receptor antagonist delivery methods for acute migraine.
The bigger picture
The gepant drug class represents a major advance in migraine treatment, moving away from non-specific pain relievers toward therapies that target the underlying CGRP pathway. This analysis shows the class is consistently effective regardless of delivery route. As more gepants and delivery methods (oral, nasal, injectable) become available, the choice will increasingly depend on patient preference and clinical circumstances rather than efficacy differences.
Questions still open
- Does nasal zavegepant provide clinically meaningful faster onset of action compared to oral gepants in real-world settings?
- Which patient subgroups benefit most from nasal versus oral CGRP receptor antagonist delivery?
- How do head-to-head trials (rather than network meta-analysis) compare these delivery routes?
Common questions
Is nasal zavegepant better than oral migraine pills?
What are CGRP receptor antagonists (gepants) for migraine?
Read the original research
The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature.
The journal of headache and pain, 26(1), 48
Citation
Zhu, Zixiang; Tang, Yanbing; Li, Longyuan; Ni, Hanyu; Liu, Meirong; Chen, Zhouqing; Wang, Zhong. (2025). The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature.. The journal of headache and pain, 26(1), 48. https://doi.org/10.1186/s10194-025-01984-7